| Literature DB >> 16777454 |
Maria E Gelain1, Marina Meli, Saverio Paltrinieri.
Abstract
In this study, the cytokine profiles of clinically healthy cats naturally infected with feline coronavirus (FCoV), of cats with feline infectious peritonitis (FIP) and of specific pathogen-free (SPF) cats were investigated in whole blood using a traditional reverse-transcriptase polymerase chain reaction (RT-PCR) assay and a semi-quantitative method of analysis based on computerised quantification of positive bands. The low inter-assay coefficient of variation recorded demonstrated that this method is highly repeatable. Compared with SPF cats, cytokine production was upregulated in most of the samples from FCoV-positive non-symptomatic cats. The appearance of a case of FIP in the cattery was associated with an increased expression of cytokines, in particular there was an increased production of IL-1beta and IFN-gamma, suggesting that these cytokines might protect infected cats from the disease. This hypothesis was also supported by the low levels of IFN-gamma recorded in blood from cats with FIP.Entities:
Mesh:
Substances:
Year: 2006 PMID: 16777454 PMCID: PMC7130096 DOI: 10.1016/j.jfms.2006.05.002
Source DB: PubMed Journal: J Feline Med Surg ISSN: 1098-612X Impact factor: 2.015
Breed, sex and age of the examined cats
| Group | Cat | Breed | Sex | Age |
|---|---|---|---|---|
| (1) FCoV | A | Persian | M | 7 years |
| B | Persian | M | 5 years | |
| C | Persian | F | 9 years | |
| D | Persian | M | 12 years | |
| (2) FIP | E | Domestic shorthair | F | 7 months |
| F | Maine Coon | F | 1 year | |
| G | Domestic shorthair | F | 8 months | |
| (3) SPF | H | Domestic shorthair | M | 10 years |
| I | Domestic shorthair | M | 1 year | |
| L | Domestic shorthair | M | 1 year | |
List of the primers and thermal cycling protocols used in the different RT-PCR cytokine assays
| Cytokine | Primer sequence | Product size (bp) | Annealing temperature (°C) | Number of cycles |
|---|---|---|---|---|
| IL-1β | Forward: AGTACCTGAACTCACCAGTG | 358 | 59 | 35 |
| Reverse: TAGTCCTGTGACTGTATGGC | ||||
| IL-4 | Forward: GCATTTACCAGCACCTTCG | 330 | 55 | 35 |
| Reverse: GATCGCTTTTAGCCTTTCC | ||||
| IL-6 | Forward: TGCCTGACAAGAATCACTACT | 333 | 55 | 35 |
| Reverse: GAACTACAGCAATCTTAGATG | ||||
| IL-10 | Forward: CTGCACCCACTTCTCAGTCAGC | 332 | 59 | 35 |
| Reverse: CCACCACCTTGCTCTTGTTT | ||||
| IL-12p40 | Forward: CAAAGAATTTGCAGATGCTGG | 462 | 55 | 35 |
| Reverse: ATGTCCCTGATGAAGAAGC | ||||
| TNF-α | Forward: CTGCAACTAATCAACCCTC | 423 | 57 | 35 |
| Reverse: TCAGCGCTGAGTCGATC | ||||
| IFN-γ | Forward: TGGTGGGTCGCTTTTCGTAG | 85 | 59 | 38 |
| Reverse: GAAGGAGACAATTTGGCTTTGAA | ||||
| GAPDH | Forward: TCTTCCAGGAGCGAGATCC | 398 | 55 | 35 |
| Reverse: AGGGATGATGTTCTGGCAGC | ||||
| P205 | GGCAACCCGATGTTTAAAACTGG | 223 | 62 | 40 |
| P211 | CACTAGATCCAGACGTTAGCTC |
DeLaurier et al 2002.
Gunn-Moore et al 1998.
Harley et al 1999.
Rottman et al 1995.
Leutenegger et al 1999.
Herrewegh et al 1995.
Results of serology, PCR on faeces, and qualitative cytokine expression in cats of group 1. Time intervals: 90 days from T1 to T2, 35 days from T2 to T3 and from T3 to T4 and 70 days from T4 to T5. Cases of FIP occurred 12 days after sampling 3 and 30 days after sampling 5
| Sampling number | Cat | Anti-FCoV | FCoV PCR | IL-1β | IL-4 | IL-6 | IL-10 | IL-12p40 | IFNγ | TNFα |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | A | 1:100 | + | + | + | − | − | + | − | − |
| B | 1:100 | + | + | − | − | − | + | − | − | |
| C | 1:100 | + | + | − | − | − | − | − | − | |
| D | 1:400 | + | + | + | − | − | − | − | − | |
| 2 | A | 1:200 | + | + | − | − | − | − | − | − |
| B | 1:1.600 | + | + | + | − | − | − | − | − | |
| C | 1:800 | + | + | + | − | + | − | + | − | |
| D | 1:50 | + | + | − | − | + | − | − | − | |
| 3 | A | 1:400 | + | + | + | + | + | + | + | + |
| B | 1:800 | − | + | + | − | − | + | − | − | |
| D | 1:400 | + | + | + | − | − | + | − | − | |
| 4 | A | 1:400 | − | + | + | − | − | + | + | − |
| C | 1:800 | + | + | − | − | − | + | − | − | |
| D | 1:50 | + | + | + | − | − | + | − | − | |
| 5 | A | 1:3.200 | + | + | + | − | − | + | + | + |
| B | 1:400 | − | + | + | − | − | − | + | − | |
| C | 1:3.200 | + | + | + | + | − | + | + | − | |
| D | 1:50 | + | + | − | − | − | + | + | + | |
Fig 1Repeatability of RT-PCR among different session of tests. RT-PCR products from sampling 2 of cats A (lanes 2 and 3), B (lanes 5 and 6), C (lanes 8 and 9), and D (lanes 11 and 12). Lane 1: 100 bp standard marker. The results here reported correspond to batches 2 (A) and 6 (B) of Table 4.
Scheme of the samples in which IL-1β was repeatedly determined
| Cat | Sampling number | Batch 2 | Batch 3 | Batch 4 | Batch 5 | Batch 6 | Batch 7 | Batch 8 | Mean | SD | CV |
|---|---|---|---|---|---|---|---|---|---|---|---|
| A (FCoV) | 2 | 68.8 | 58.6 | 65.5 | 64.3 | 5.2 | 8.1 | ||||
| 3 | 85.8 | 89.3 | 87.5 | 2.5 | 2.9 | ||||||
| 4 | 85.2 | 94.6 | 89.9 | 6.7 | 7.4 | ||||||
| 5 | 91.4 | 92.6 | 92.0 | 0.8 | 0.9 | ||||||
| B (FCoV) | 2 | 47.6 | 53.2 | 50.4 | 4.0 | 7.9 | |||||
| 3 | 68.8 | 83.3 | 76.0 | 10.2 | 13.5 | ||||||
| 4 | 80.9 | 72.1 | 76.5 | 6.2 | 8.1 | ||||||
| C (FCoV) | 2 | 76.8 | 79.9 | 78.4 | 2.2 | 2.9 | |||||
| 3 | 39.8 | 55.3 | 47.6 | 11.0 | 23.1 | ||||||
| D (FCoV) | 2 | 46.1 | 54.3 | 50.2 | 5.8 | 11.6 | |||||
| 3 | 74.8 | 77.4 | 76.1 | 1.8 | 2.4 | ||||||
| H (SPF) | 33.4 | 56.2 | 65.0 | 55.2 | 57.3 | 53.4 | 11.8 | 22.2 | |||
Values are expressed as percentage of the mean intensity of the internal calibrator (500 bp ladder) of each batch. The analysis of the repeatability of the computerised quantification of IL-1β expression was performed by examining mean, standard deviation (SD) and coefficient of variation (CV). None of the samples included in batch 1 were repeatedly analysed so no columns referring to batch 1 are therefore included in this table.
Fig 2Examples of RT-PCR products for IL-12p40 (A) IL-4 (B) and IFN-γ (C) recorded in FCoV-exposed cats.
Lymphocyte percentage and cytokine expression, expressed as percentages of intensity of the internal calibrator included in the corresponding batch of tests. Values referred to each group were expressed as median, I and III quartiles, and 95° percentile ranges (between parentheses)
| Cat | Sampling number | Lymph % | IL-1β | IL-4 | IL-6 | IL-10 | IL-12p40 | IFN-γ | TNF-α |
|---|---|---|---|---|---|---|---|---|---|
| A | 1 | 36 | 63.1 | 41.3 | 0.0 | 0.0 | 55.3 | 0.0 | 0.0 |
| 2 | 38 | 64.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| 3 | 38 | 87.5 | 51.1 | 50.1 | 19.7 | 72.4 | 8.3 | 61.1 | |
| 4 | 31 | 89.9 | 32.0 | 0.0 | 0.0 | 52.4 | 21.4 | 0.0 | |
| 5 | 35 | 92.0 | 39.7 | 0.0 | 0.0 | 72.5 | 26.4 | 62.3 | |
| B | 1 | 42 | 40.1 | 0.0 | 0.0 | 0.0 | 61.5 | 0.0 | 0.0 |
| 2 | 51 | 53.2 | 38.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| 3 | 28 | 76.0 | 80.6 | 0.0 | 0.0 | 48.2 | 0.0 | 0.0 | |
| 5 | 52 | 76.5 | 42.3 | 0.0 | 0.0 | 0.0 | 23.2 | 0.0 | |
| C | 1 | 25 | 56.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| 2 | 50 | 80.0 | 36.0 | 0.0 | 53.2 | 0.0 | 31.6 | 0.0 | |
| 4 | 26 | 47.5 | 0.0 | 0.0 | 0.0 | 49.6 | 0.0 | 0.0 | |
| 5 | 39 | 93.8 | 50.4 | 41.7 | 0.0 | 82.0 | 27.3 | 0.0 | |
| D | 1 | 38 | 31.7 | 48.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| 2 | 35 | 54.3 | 0.0 | 0.0 | 58.2 | 0.0 | 0.0 | 0.0 | |
| 3 | 57 | 76.1 | 24.0 | 0.0 | 0.0 | 42.7 | 0.0 | 0.0 | |
| 4 | 35 | 71.6 | 40.8 | 0.0 | 0.0 | 52.8 | 0.0 | 0.0 | |
| 5 | 48 | 93.0 | 0.0 | 0.0 | 0.0 | 90.0 | 29.1 | 61.6 | |
| Group 1 (FCoV) | 73.8 | 37.1 | 0.0 | 0.0 | 48.9 | 0.0 | 0.0 | ||
| 54.8–85.6 | 0.0–42.1 | 0.0–0.0 | 0.0–0.0 | 00–60.0 | 0.0–22.8 | 0.0–0.0 | |||
| (35.3–93.5) | (0.0–68.1) | (0.0–46.5) | (0.0–56.1) | (0.0–86.6) | (0.0–30.5) | (0.0–62.0) | |||
| E | 87.1 | 20.4 | 0.0 | 0.0 | 78.7 | 7.4 | 65.7 | ||
| F | 20.8 | 0.0 | 27.2 | 0.0 | 0.0 | 0.0 | 0.0 | ||
| G | 34.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | ||
| Group 2 (FIP) | 34.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | ||
| 27.4–60.6 | 0.0–10.2 | 0.0–13.6 | 0.0–0.0 | 0.0–39.4 | 0.0–3.7 | 0.0–32.9 | |||
| (21.5–84.4) | (0.0–19.4) | (0.0–25.8) | (0.0–0.0) | (0.0–74.8) | (0.0–7.0) | (0.0–62.4) | |||
| H | 53.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | ||
| I | 44.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 51.4 | ||
| L | 55.9 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | ||
| Group 3 (SPF) | 53.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | ||
| 48.8–54.7 | 0.0–0.0 | 0.0–0.0 | 0.0–0.0 | 0.0–0.0 | 0.0–0.0 | 0.0–25.7 | |||
| (44.7–55.8) | (0.0–0.0) | (0.0–0.0) | (0.0–0.0) | (0.0–0.0) | (0.0–0.0) | (0.0–48.8) | |||
Semi-quantitative image analysis of RT-PCR products: median, I and III quartiles, and 95° percentile ranges (between parentheses) recorded in the five samplings of FCoV infected cats, in FIP cats and in SPF cats
| Cytokine | Sampling 1 | Sampling 2 | Sampling 3 | Sampling 4 | Sampling 5 | Group 2 (FIP) | Group 3 (SPF) |
|---|---|---|---|---|---|---|---|
| IL-1β | 48.2 | 59.3 | 76.1 | 71.6 | 92.5*§ | 34.0 | 53.4 |
| 38.0–58.0 | 54.0–68.2 | 76.1–81.8 | 59.6–80.8 | 88.1–93.2 | 27.4–60.6 | 48.8–54.7 | |
| (32.3–62.6) | (53.3–78.8) | (76.0–86.9) | (48.7–89.0) | (77.7–93.7) | (21.5–84.4) | (44.7–55.8) | |
| IL-4 | 20.7 | 18.0 | 51.9 | 32.0 | 41.0 | 0.0 | 0.0 |
| 0.0–43.1 | 0.0–36.6 | 37.6–65.9 | 16.0–36.4 | 29.8–44.3 | 0.0–10.2 | 0.0–0.0 | |
| (0.0–47.9) | (0.0–38.0) | (51.1–79.1) | (1.6–40.4) | (3.0–49.8) | (0.0–19.4) | (0.0–0.0) | |
| IL-6 | 0.0 | 0.0 | 16.7 | 0.0 | 0.0 | 0.0 | 0.0 |
| 0.0–0.0 | 0.0–0.0 | 0.0–25.1 | 0.0–0.0 | 0.0–10.4 | 0.0–13.6 | 0.0–0.0 | |
| (0.0–0.0) | (0.0–0.0) | (0.0–47.6) | (0.0–0.0) | (0.0–38.6) | (0.0–25.8) | (0.0–0.0) | |
| IL-10 | 0.0 | 26.6 | 6.6 | 0.0 | 0.0 | 0.0 | 0.0 |
| 0.0–0.0 | 0.0–54.5 | 0.0–9.9 | 0.0–0.0 | 0.0–0.0 | 0.0–0.0 | 0.0–0.0 | |
| (0.0–0.0) | (0.0–57.8) | (0.0–18.7) | (0.0–0.0) | (0.0–0.0) | (0.0–0.0) | (0.0–0.0) | |
| IL-12p40 | 27.7 | 0.0 | 54.4 | 52.4 | 77.3 | 0.0 | 0.0 |
| 0.0–56.9 | 0.0–0.0 | 45.5–60.3 | 51.0–52.6 | 54.4–84.0 | 0.0–39.4 | 0.0–0.0 | |
| (0.0–61.0) | (0.0–0.0) | (48.2–71.2) | (49.7–52.8) | (5.4–89.4) | (0.0–74.8) | (0.0–0.0) | |
| IFN-γ | 0.0 | 0.0 | 2.8 | 0.0 | 26.9*§ | 0.0 | 0.0 |
| 0.0–0.0 | 0.0–7.9 | 0.0–4.2 | 0.0–10.7 | 25.6–27.8 | 0.0–3.7 | 0.0–0.0 | |
| (0.0–0.0) | (0.0–29.2) | (0.0–7.9) | (0.0–20.3) | (23.4–29.0) | (0.0–7.0) | (0.0–0.0) | |
| TNF-α | 0.0 | 0.0 | 20.4 | 0.0 | 30.8 | 0.0 | 0.0 |
| 0.0–0.0 | 0.0–0.0 | 0.0–30.6 | 0.0–0.0 | 0.0–61.8 | 0.0–32.9 | 0.0–25.7 | |
| (0.0–0.0) | (0.0–0.0) | (0.0–58.0) | (0.0–0.0) | (0.0–62.2) | (0.0–62.4) | (0.0–48.8) |
*P < 0.05 vs sampling 1.
§P < 0.01 vs FIP, SPF.